A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT04667052
- Locations
- 🇺🇸
WCCT Global, LLC, Cypress, California, United States
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents
- Conditions
- Healthy
- Interventions
- Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT04661397
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 253
- Registration Number
- NCT04662580
- Locations
- 🇺🇸
University of California, Los Angeles School of Medicine, Los Angeles, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Radiation: Conventional radiation therapyRadiation: Hypo-fractioned radiation therapy
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 518
- Registration Number
- NCT04658862
- Locations
- 🇫🇷
Hôpital Européen, Marseille, France
🇬🇷Bioclinic - Thessaloniki, Thessaloniki, Greece
🇬🇷Euromedica General Clinic, Thessaloniki, Greece
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- Conditions
- Lymphoma, Non-HodgkinChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT04657224
- Locations
- 🇲🇩
Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sheba Medical Center, Ramat Gan, Israel
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04655807
- Locations
- 🇺🇸
Medisphere Medical Research Center, Llc, Evansville, Indiana, United States
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
- Conditions
- Prostatic NeoplasmsAdenocarcinoma
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 247
- Registration Number
- NCT04644770
- Locations
- 🇺🇸
East Jefferson General Hospital, Metairie, Louisiana, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT04640623
- Locations
- 🇫🇷
Polyclinique de Limoges - Francois Chenieux, Limoges, France
🇮🇹Ospedale San Martino, Genova, Italy
🇮🇹Ospedale San Raffaele, Milan, Italy
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT04633447
- Locations
- 🇪🇸
Hosp Regional Univ de Malaga, Malaga, Spain
🇪🇸Hosp Univ A Coruna, A Coruna, Spain
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 510
- Registration Number
- NCT04634552
- Locations
- 🇧🇪
UCL - Saint Luc, Brussels, Belgium
🇧🇪UZ Antwerpen, Edegem, Belgium
🇧🇪UZ Leuven, Leuven, Belgium